Stoke Therapeutics (STOK) Other Operating Expenses (2019 - 2025)
Stoke Therapeutics (STOK) posted quarterly Other Operating Expenses of $152.4 million for Q4 2025, up 439.1% quarter-over-quarter from -$44.9 million in Q2 2025.
Stoke Therapeutics (STOK) Other Operating Expenses (2019 - 2025) Analysis & Trends
Stoke Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $152.4 million for Q4 2025.
- In Q4 2025, Other Operating Expenses changed N/A year-over-year to $152.4 million; the TTM figure through Mar 2026 stood at $107.4 million (up 379.27% YoY), while the FY2023 annual figure was -$133.6 million, changed N/A from the prior year.
- Other Operating Expenses for Q4 2025 stood at $152.4 million, up from -$44.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was $152.4 million in Q4 2025, with the low at -$133.6 million in Q4 2023.
- The 3-year median for Other Operating Expenses is -$41.7 million (2024), against an average of -$16.2 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 152.37 Mn |
| Jun 30, 2025 | -44.93 Mn |
| Sep 30, 2024 | -38.47 Mn |
| Dec 31, 2023 | -133.63 Mn |
| Dec 31, 2019 | 1,000.00 |